These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

363 related articles for article (PubMed ID: 7560060)

  • 1. Absence of the mdr1a P-Glycoprotein in mice affects tissue distribution and pharmacokinetics of dexamethasone, digoxin, and cyclosporin A.
    Schinkel AH; Wagenaar E; van Deemter L; Mol CA; Borst P
    J Clin Invest; 1995 Oct; 96(4):1698-705. PubMed ID: 7560060
    [TBL] [Abstract][Full Text] [Related]  

  • 2. P-glycoprotein in the blood-brain barrier of mice influences the brain penetration and pharmacological activity of many drugs.
    Schinkel AH; Wagenaar E; Mol CA; van Deemter L
    J Clin Invest; 1996 Jun; 97(11):2517-24. PubMed ID: 8647944
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Lack of difference in pulmonary absorption of digoxin, a P-glycoprotein substrate, in mdr1a-deficient and mdr1a-competent mice.
    Manford F; Riffo-Vasquez Y; Spina D; Page CP; Hutt AJ; Moore V; Johansson F; Forbes B
    J Pharm Pharmacol; 2008 Oct; 60(10):1305-10. PubMed ID: 18812023
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Pluronic P85 enhances the delivery of digoxin to the brain: in vitro and in vivo studies.
    Batrakova EV; Miller DW; Li S; Alakhov VY; Kabanov AV; Elmquist WF
    J Pharmacol Exp Ther; 2001 Feb; 296(2):551-7. PubMed ID: 11160643
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Complete in vivo reversal of P-glycoprotein pump function in the blood-brain barrier visualized with positron emission tomography.
    Hendrikse NH; Schinkel AH; de Vries EG; Fluks E; Van der Graaf WT; Willemsen AT; Vaalburg W; Franssen EJ
    Br J Pharmacol; 1998 Aug; 124(7):1413-8. PubMed ID: 9723952
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Penetration of dexamethasone into brain glucocorticoid targets is enhanced in mdr1A P-glycoprotein knockout mice.
    Meijer OC; de Lange EC; Breimer DD; de Boer AG; Workel JO; de Kloet ER
    Endocrinology; 1998 Apr; 139(4):1789-93. PubMed ID: 9528963
    [TBL] [Abstract][Full Text] [Related]  

  • 7. In vitro to in vivo comparison of the substrate characteristics of sorafenib tosylate toward P-glycoprotein.
    Gnoth MJ; Sandmann S; Engel K; Radtke M
    Drug Metab Dispos; 2010 Aug; 38(8):1341-6. PubMed ID: 20413726
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Digoxin-cyclosporin A interaction: modulation of the multidrug transporter P-glycoprotein in the kidney.
    Okamura N; Hirai M; Tanigawara Y; Tanaka K; Yasuhara M; Ueda K; Komano T; Hori R
    J Pharmacol Exp Ther; 1993 Sep; 266(3):1614-9. PubMed ID: 8103797
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Interaction of cytochrome P450 3A inhibitors with P-glycoprotein.
    Yasuda K; Lan LB; Sanglard D; Furuya K; Schuetz JD; Schuetz EG
    J Pharmacol Exp Ther; 2002 Oct; 303(1):323-32. PubMed ID: 12235267
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Effect of interferon-gamma on the pharmacokinetics of digoxin, a P-glycoprotein substrate, intravenously injected into the mouse.
    Kawaguchi H; Matsui Y; Watanabe Y; Takakura Y
    J Pharmacol Exp Ther; 2004 Jan; 308(1):91-6. PubMed ID: 14569074
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Disposition of ivermectin and cyclosporin A in CF-1 mice deficient in mdr1a P-glycoprotein.
    Kwei GY; Alvaro RF; Chen Q; Jenkins HJ; Hop CE; Keohane CA; Ly VT; Strauss JR; Wang RW; Wang Z; Pippert TR; Umbenhauer DR
    Drug Metab Dispos; 1999 May; 27(5):581-7. PubMed ID: 10220486
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Distribution of STI-571 to the brain is limited by P-glycoprotein-mediated efflux.
    Dai H; Marbach P; Lemaire M; Hayes M; Elmquist WF
    J Pharmacol Exp Ther; 2003 Mar; 304(3):1085-92. PubMed ID: 12604685
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Contribution of the murine mdr1a P-glycoprotein to hepatobiliary and intestinal elimination of cationic drugs as measured in mice with an mdr1a gene disruption.
    Smit JW; Schinkel AH; Müller M; Weert B; Meijer DK
    Hepatology; 1998 Apr; 27(4):1056-63. PubMed ID: 9537446
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Full blockade of intestinal P-glycoprotein and extensive inhibition of blood-brain barrier P-glycoprotein by oral treatment of mice with PSC833.
    Mayer U; Wagenaar E; Dorobek B; Beijnen JH; Borst P; Schinkel AH
    J Clin Invest; 1997 Nov; 100(10):2430-6. PubMed ID: 9366556
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Increased accumulation of doxorubicin and doxorubicinol in cardiac tissue of mice lacking mdr1a P-glycoprotein.
    van Asperen J; van Tellingen O; Tijssen F; Schinkel AH; Beijnen JH
    Br J Cancer; 1999 Jan; 79(1):108-13. PubMed ID: 10408701
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Minocycline and riluzole brain disposition: interactions with p-glycoprotein at the blood-brain barrier.
    Milane A; Fernandez C; Vautier S; Bensimon G; Meininger V; Farinotti R
    J Neurochem; 2007 Oct; 103(1):164-73. PubMed ID: 17635670
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Comparison of P-glycoprotein-mediated drug-digoxin interactions in Caco-2 with human and rodent intestine: relevance to in vivo prediction.
    Collett A; Tanianis-Hughes J; Carlson GL; Harwood MD; Warhurst G
    Eur J Pharm Sci; 2005 Dec; 26(5):386-93. PubMed ID: 16153812
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Absence or pharmacological blocking of placental P-glycoprotein profoundly increases fetal drug exposure.
    Smit JW; Huisman MT; van Tellingen O; Wiltshire HR; Schinkel AH
    J Clin Invest; 1999 Nov; 104(10):1441-7. PubMed ID: 10562306
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Differential involvement of multidrug resistance-associated protein 1 and P-glycoprotein in tissue distribution and excretion of grepafloxacin in mice.
    Sasabe H; Kato Y; Suzuki T; Itose M; Miyamoto G; Sugiyama Y
    J Pharmacol Exp Ther; 2004 Aug; 310(2):648-55. PubMed ID: 15131241
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Multidrug resistance protein 2 is an important determinant of paclitaxel pharmacokinetics.
    Lagas JS; Vlaming ML; van Tellingen O; Wagenaar E; Jansen RS; Rosing H; Beijnen JH; Schinkel AH
    Clin Cancer Res; 2006 Oct; 12(20 Pt 1):6125-32. PubMed ID: 17062689
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 19.